NON-UNIVERSITY PAIN CARE OF TUMOR PATIENTS IN AN OUTPATIENT CLINIC SETTING - AS MATTERS STAND f.meyer@med.ovgu.de

PE017

NON-UNIVERSITY PAIN CARE OF TUMOR PATIENTS IN AN OUTPATIENT CLINIC SETTING - AS MATTERS STAND

3

 

 

 

 

Germany

Poster Exhibition only

Based on the multiple descriptions of “opioid epidemic“ in the U.S. (CDC; McCarthy; Bosse et al.), the issue is still under discussion. Question: How is the general supply with analgetics (WHO, psychotropics) in patients with tumor lesions, who were admitted to the Division of Pain Therapy of the University Hospital of Magdeburg (Germany)?

Retrospective, pseudonymized, topic-related data aquisition during a defined study period 1-4/2025.

In total, 13 patients were enrolled. All options of the MASK scheme were registered as pain site. Tumor lesions were found in the lung, skin and, in particular, in the digestive tract; 9 patients had metastases. Three patients did not receive any medication prior to admittance, 5 received opioids (out of them one with Tapentadol), 10 had NSAIDs (in the majority of cases, Metamizol). After admittance, 10 patients were administered a strong, 2 a weak opioid. Despite the short time period, in 7 patients a pain reduction was observed.

The discussion on the opioid use leads to a shortage of this specific care in tumor patients. Out of the 5 patients with a strong opioid, there was only 1 patient with an additional pro re nata medication. The oversupply with Metamizol is not justified.